相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A novel anti-viral role for STAT3 in IFN-α signalling responses
Rebecca Mahony et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-cell Lymphoma
Fen Zhu et al.
MOLECULAR CANCER RESEARCH (2017)
Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype
X. Guo et al.
ONCOGENE (2017)
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2017)
Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma
Lixin Rui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
A mix of S and.S variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture
M. Zheng et al.
ONCOGENESIS (2016)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
Priscilla N. Kelly et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
Chi Young Ok et al.
CLINICAL CANCER RESEARCH (2014)
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
Umberto Vitolo et al.
LANCET ONCOLOGY (2014)
IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage
HyeonJoo Cheon et al.
EMBO JOURNAL (2013)
Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Xin Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Large-scale gene function analysis with the PANTHER classification system
Huaiyu Mi et al.
NATURE PROTOCOLS (2013)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
STAT3 Targets Suggest Mechanisms of Aggressive Tumorigenesis in Diffuse Large B-Cell Lymphoma
Jennifer Hardee et al.
G3-GENES GENOMES GENETICS (2013)
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yibin Yang et al.
CANCER CELL (2012)
Janus Kinase Deregulation in Leukemia and Lymphoma
Edwin Chen et al.
IMMUNITY (2012)
Ruxolitinib
Ruben A. Mesa et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma
Anna Scuto et al.
CANCER RESEARCH (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Mechanisms of Disease: Aggressive Lymphomas.
Georg Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oncogenic Activation of NF-kappa B
Louis M. Staudt
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno et al.
NATURE (2009)
MEME SUITE: tools for motif discovery and searching
Timothy L. Bailey et al.
NUCLEIC ACIDS RESEARCH (2009)
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma
Lloyd T. Lam et al.
BLOOD (2008)
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Peter H. Wiernik et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Model-based Analysis of ChIP-Seq (MACS)
Yong Zhang et al.
GENOME BIOLOGY (2008)
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
B. Belinda Ding et al.
BLOOD (2008)
Interferons at age 50: past, current and future impact on biomedicine
Ernest C. Borden et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
NF-κB2 mutation targets TRAF1 to induce lymphomagenesis
Baochun Zhang et al.
BLOOD (2007)
Role of STAT3 in type I interferon responses - Negative regulation of STAT1-dependent inflammatory gene activation
Hao H. Ho et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A loss-of-function RNA interference screen for molecular targets in cancer
VN Ngo et al.
NATURE (2006)
Alternative activation of STAT1 and STAT3 in response to interferon-γ
YL Qing et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Mutational switch of an IL-6 response to an interferon-γ-like response
AP Costa-Pereira et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
分享论文
